{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:05Z","timestamp":1791571745292,"version":"4.3.4"},"reference-count":40,"publisher":"Massachusetts Medical Society","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.1056\/nejmoa2303194","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:02:13Z","timestamp":1693414933000},"page":"1009-1022","source":"Crossref","is-referenced-by-count":105,"title":["Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1056","volume":"389","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette J.","family":"Vangsted","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Arnao","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatchada","family":"Karanes","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez Otero","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Casas-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Spirli","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Poon","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Li","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gong","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Wong","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Lamba","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Pierce","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amatangelo","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Peluso","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Maciag","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Katz","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pourdehnad","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"From Dana\u2013Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB (N.J.B.) \u2014 both in Canada; NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust (R.P.), the Institute of Cancer Research (C.P.), and the Royal Marsden NHS Foundation Trust (C.P.), London, and the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.) \u2014 all in the United Kingdom; University Hospital of Salamanca\/IBSAL, Salamanca (M.-V.M.), the Department of Hematology, Hospital 12 de Octubre, Department of Medicine, School of Medicine, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid (J.M.-L.), Hospital Universitari La Fe, Valencia (M.A.), Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Cl\u00ednica U..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238527"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13046"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913143"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01928"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","unstructured":"Lopez-Girona A Havens CG Lu G et al. CC-92480 is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells. Blood 2019;134:Suppl 1:1812-1812. abstract.","DOI":"10.1182\/blood-2019-124338"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2011.03.006"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098202"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.8.2004"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.add7574"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","unstructured":"Wong L Jim\u00e9nez Nu\u00f1ez MD Bahlis NJ et al. Pharmacodynamic (PD) responses drive dose\/schedule selection of CC-92480 a novel CELMoD agent in a phase 1 dose-escalation study in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 2020;38:Suppl:8531-8531. abstract (https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.15_suppl.8531).","DOI":"10.1200\/JCO.2020.38.15_suppl.8531"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","unstructured":"Wong L Narla RK Leisten J et al. CC-92480 a novel cereblon E3 ligase modulator is synergistic with dexamethasone bortezomib and daratumumab in multiple myeloma. Blood 2019;134:Suppl 1:1815-1815. abstract (https:\/\/ashpublications.org\/blood\/article\/134\/Supplement_1\/1815\/427718\/CC-92480-a-Novel-Cereblon-E3-Ligase-Modulator-Is).","DOI":"10.1182\/blood-2019-124345"},{"key":"e_1_3_5_24_2","unstructured":"Wong L Carrancio S Mendy D et al. The novel CELMoD agent CC-92480: translation of preclinical data to a phase 1 clinical trial design. HemaSphere 2020:EP895-EP895 (https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/294812\/lilly.wong.the.novel.celmod.agent.cc-92480.translation.of.preclinical.data.to.html)."},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543400902802409"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00568-3"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.641"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.011"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25134"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","unstructured":"Richardson PG Sandhu I Oriol A et al. Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 2022;22:Suppl:S33-S33. abstract (https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(22)00326-3\/fulltext).","DOI":"10.1016\/S2152-2650(22)00326-3"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007081"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2303194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:52:24Z","timestamp":1749667944000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2303194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9,14]]}},"alternative-id":["10.1056\/NEJMoa2303194"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2303194","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}